In 2023, the production value of biotechnology research and experimental development in Norway stood at 409.0 million Euros. The forecasted data from 2024 to 2028 shows a steady increase in production value. For 2024, the value is projected to be 427.2 million Euros, rising further to 445.8 million Euros in 2025, 464.2 million Euros in 2026, 482.4 million Euros in 2027, and reaching 500.4 million Euros in 2028. This demonstrates a consistent year-on-year growth.
Year-on-year variations in percentage from 2024 to 2028 are as follows:
- 2024: 4.4% increase from 2023
- 2025: 4.4% increase from 2024
- 2026: 4.1% increase from 2025
- 2027: 3.9% increase from 2026
- 2028: 3.7% increase from 2027
The compound annual growth rate (CAGR) from 2024 to 2028 is approximately 4.1%, indicating a robust growth trend over the five-year period.
Future trends to watch for include advancements in biotechnological innovations, increased investment in research and development, strategic partnerships within the biotechnology sector, and governmental policies that might further accelerate growth. Monitoring shifts in global biotechnology trends and potential market disruptions will also be crucial.
